Last reviewed · How we verify
Ketas (IBUDILAST)
At a glance
| Generic name | IBUDILAST |
|---|---|
| Sponsor | Kyorin Pharmaceutical |
| Drug class | ibudilast |
| Target | cAMP-specific 3',5'-cyclic phosphodiesterase 4A |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
| First approval | 1989 |
Approved indications
- Asthma
Common side effects
- Emesis
- Salivation
- Vocalization
- Erratic recovery
- Prolonged recovery
- Spastic jerking movements
- Muscular tremors
- Hypertonicity
- Dyspnea
- Myoclonic jerking
- Mild tonic convulsions
Serious adverse events
- Respiratory depression
- Cyanosis
- Convulsions
- Opisthotonos
- Cardiac arrest
Key clinical trials
- Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS
- Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS (PHASE2,PHASE3)
- RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (PHASE2,PHASE3)
- Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users (PHASE2)
- Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma (PHASE1,PHASE2)
- Ibudilast for Treating Alcohol Use Disorder (PHASE2)
- Ibudilast for the Treatment of Alcohol Use Disorder (PHASE2)
- Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketas CI brief — competitive landscape report
- Ketas updates RSS · CI watch RSS
- Kyorin Pharmaceutical portfolio CI